115 related articles for article (PubMed ID: 11809706)
21. Id1 transcription inhibitor-matrix metalloproteinase 9 axis enhances invasiveness of the breakpoint cluster region/abelson tyrosine kinase-transformed leukemia cells.
Nieborowska-Skorska M; Hoser G; Rink L; Malecki M; Kossev P; Wasik MA; Skorski T
Cancer Res; 2006 Apr; 66(8):4108-16. PubMed ID: 16618731
[TBL] [Abstract][Full Text] [Related]
22. [Cyclin D2 expression in chronic myelogenous leukemia].
Song JM; Xu D; Fan EJ; Xu SR; Li D; Zhao CH
Zhonghua Xue Ye Xue Za Zhi; 2004 Feb; 25(2):103-5. PubMed ID: 14990053
[TBL] [Abstract][Full Text] [Related]
23. Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia.
Møller GM; Frost V; Melo JV; Chantry A
FEBS Lett; 2007 Apr; 581(7):1329-34. PubMed ID: 17349636
[TBL] [Abstract][Full Text] [Related]
24. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
[TBL] [Abstract][Full Text] [Related]
25. p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
Brusa G; Benvenuti M; Mazzacurati L; Mancini M; Pattacini L; Martinelli G; Barbieri E; Greenberger JS; Baccarani M; Santucci MA
Haematologica; 2003 Jun; 88(6):622-30. PubMed ID: 12801837
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of bcr-abl and/or c-abl gene expression by small interfering, double-stranded RNAs: cross-talk with cell proliferation factors and other oncogenes.
Ohba H; Zhelev Z; Bakalova R; Ewis A; Omori T; Ishikawa M; Shinohara Y; Baba Y
Cancer; 2004 Sep; 101(6):1390-403. PubMed ID: 15368327
[TBL] [Abstract][Full Text] [Related]
27. BCR/ABL expression of myeloid progenitors increases beta1-integrin mediated adhesion to stromal cells.
Fierro FA; Taubenberger A; Puech PH; Ehninger G; Bornhauser M; Muller DJ; Illmer T
J Mol Biol; 2008 Apr; 377(4):1082-93. PubMed ID: 18313694
[TBL] [Abstract][Full Text] [Related]
28. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
Wu Y; Chen YZ; Huang HF; Chen P; Lu LH
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
[TBL] [Abstract][Full Text] [Related]
29. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
30. Early events in leukemogenesis in P190Bcr-abl transgenic mice.
Salloukh HF; Vowles I; Heisterkamp N; Groffen J; Laneuville P
Oncogene; 2000 Sep; 19(38):4362-74. PubMed ID: 10980612
[TBL] [Abstract][Full Text] [Related]
31. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism.
Fernández de Mattos S; Essafi A; Soeiro I; Pietersen AM; Birkenkamp KU; Edwards CS; Martino A; Nelson BH; Francis JM; Jones MC; Brosens JJ; Coffer PJ; Lam EW
Mol Cell Biol; 2004 Nov; 24(22):10058-71. PubMed ID: 15509806
[TBL] [Abstract][Full Text] [Related]
32. BCR/ABL confers growth factor independence upon a murine myeloid cell line.
Mandanas RA; Boswell HS; Lu L; Leibowitz D
Leukemia; 1992 Aug; 6(8):796-800. PubMed ID: 1379313
[TBL] [Abstract][Full Text] [Related]
33. Cyclin D2 controls B cell progenitor numbers.
Mohamedali A; Soeiro I; Lea NC; Glassford J; Banerji L; Mufti GJ; Lam EW; Thomas NS
J Leukoc Biol; 2003 Dec; 74(6):1139-43. PubMed ID: 14612431
[TBL] [Abstract][Full Text] [Related]
34. Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression.
Klucher KM; Lopez DV; Daley GQ
Blood; 1998 May; 91(10):3927-34. PubMed ID: 9573031
[TBL] [Abstract][Full Text] [Related]
35. Signaling by ABL oncogenes through cyclin D1.
Afar DE; McLaughlin J; Sherr CJ; Witte ON; Roussel MF
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9540-4. PubMed ID: 7568169
[TBL] [Abstract][Full Text] [Related]
36. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells.
Cortez D; Reuther G; Pendergast AM
Oncogene; 1997 Nov; 15(19):2333-42. PubMed ID: 9393877
[TBL] [Abstract][Full Text] [Related]
37. Bcr-Abl is a "molecular switch" for the decision for growth and differentiation in hematopoietic stem cells.
Era T
Int J Hematol; 2002 Jul; 76(1):35-43. PubMed ID: 12138893
[TBL] [Abstract][Full Text] [Related]
38. The biology of Abl during hemopoietic stem cell differentiation and development.
Chung SW; Wong PM
Oncogene; 1995 Apr; 10(7):1261-8. PubMed ID: 7731675
[No Abstract] [Full Text] [Related]
39. Pleiotropic p27(Kip1), BCR-ABL and leukemic stem cell: the trio in concert.
Sengupta A; Banerjee S
Leukemia; 2007 Dec; 21(12):2559-61. PubMed ID: 17611557
[No Abstract] [Full Text] [Related]
40. CCR7 is involved in BCR-ABL/STAP-2-mediated cell growth in hematopoietic Ba/F3 cells.
Kubo K; Iwakami M; Muromoto R; Inagaki T; Kitai Y; Kon S; Sekine Y; Oritani K; Matsuda T
Biochem Biophys Res Commun; 2015 Aug; 463(4):825-31. PubMed ID: 26102025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
